Cross John Harry III 4

4 · Sonnet BioTherapeutics Holdings, Inc. · Filed Apr 8, 2022

Insider Transaction Report

Form 4
Period: 2021-12-15
Cross John Harry III
Chief Financial Officer
Transactions
  • Award

    Common Stock

    2021-12-15+66,951145,165 total
Footnotes (2)
  • [F1]On December 15, 2021, the Reporting Person was granted 66,951 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest as to 100% of the restricted stock units on January 1, 2023.
  • [F2]Includes unvested RSUs.

Documents

1 file
  • 4
    ownership.xmlPrimary